Oncological Outcomes Following Different TACE ‐Based Conversion Therapies for Intermediate‐Advanced Hepatocellular Carcinoma

Key Points

• To compare oncological outcomes among different TACE-based conversion therapies for intermediate-advanced hepatocellular carcinoma.
• Analyzed various treatment combinations, focusing on TACE, TKI, and ICI.
• Evaluated overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).
• Compared long-term survival with and without liver resection.
• The TACE+TKI+ICI combination showed a superior overall response rate (ORR).
• Patients with liver resection had significantly enhanced long-term survival compared to those without.
• Manageable adverse events (AEs) were associated with the combined therapy.